5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: Can we afford to wait for 'best evidence'?

Digestive and Liver Disease

Volumn 37, Issue 10, 2005, Pages 723-731

  Giannini, E G ^a   Kane, S V ^b   Testa, R ^a   Savarino, V ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

5 ASA; Chemoprevention; Cirrhosis; Colorectal cancer; Inflammatory bowel disease; Mesalazine

Indexed keywords

ACETYLSALICYLIC ACID; BALSALAZIDE; CYCLOOXYGENASE 2; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; OLSALAZINE; PROSTAGLANDIN SYNTHASE; REACTIVE OXYGEN METABOLITE; SALAZOSULFAPYRIDINE;

ANTINEOPLASTIC ACTIVITY; CANCER PREVENTION; CANCER RISK; CASE CONTROL STUDY; CHEMOPROPHYLAXIS; CLINICAL STUDY; COLORECTAL CANCER; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG WITHDRAWAL; ENTERITIS; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; FOLIC ACID DEFICIENCY; HIGH RISK POPULATION; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; NONHUMAN; RETROSPECTIVE STUDY; RISK REDUCTION; SHORT SURVEY; CLINICAL TRIAL; COLORECTAL TUMOR; REVIEW; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMOPREVENTION; CLINICAL TRIALS; COLORECTAL NEOPLASMS; EVIDENCE-BASED MEDICINE; HUMANS; INFLAMMATORY BOWEL DISEASES; MESALAMINE; RISK FACTORS;

EID: 28644450204     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2005.02.012     Document Type: Short Survey

References (87)

1. Ransohoff D.F. Colon cancer in ulcerative colitis. Gastroenterology 94 (1988) 1089-1091
2. Eaden J.A., and Mayberry J.F. Colorectal cancer complicating ulcerative colitis: a review. Am J Gastroenterol 95 (2000) 2710-2719
3. Sharan R., and Schoen R.E. Cancer in inflammatory bowel disease. An evidence-based analysis and guide for physicians and patients. Gastroenterol Clin North Am 31 (2002) 237-254
4. Eaden J.A., Abrams K.R., and Mayberry J.F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48 (2001) 526-535
5. Gillen C.D., Walmsley R.S., Prior P., Andrews H.A., and Allan R.N. Ulcerative colitis and Cronh's disease: a comparison of the colorectal cancer risk in extensive colitis. Crohn's disease and colorectal cancer. Gut 35 (1994) 651-655
6. Ekbom A., Helmick C., Zack M., and Adami H.-O. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet 336 (1990) 357-359
7. Bernstein C.N., Kliewer E., Wajda A., and Blanchard J.F. The incidence of cancer among patients with IBD: a population-based study. Cancer 91 (2001) 854-862
8. Itzkowitz S.H. Cancer prevention in patients with inflammatory bowel disease. Gastroenterol Clin North Am 31 (2002) 1133-1144
9. Lashner B.A., Kane S.V., and Hanauer S.B. Colon cancer surveillance in chronic ulcerative colitis: historical cohort study. Am J Gastroenterol 85 (1990) 1083-1087
10. Bernstein C.N., Shanahan F., and Weinstein W.M. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?. Lancet 343 (1994) 71-74
11. Cohen R.D., and Hanauer S.B. Surveillance colonoscopy in ulcerative colitis: is the message loud and clear?. Am J Gastroenterol 90 (1995) 2090-2092
12. Bernstein C.N., Weinstein W.M., Levine D.S., and Shanahan F. Physicians' perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. Am J Gastroenterol 90 (1995) 2106-2114
13. Provenzale D., Wong J.B., Onken J.E., and Lipscomb J. Performing a cost-effectiveness analysis: surveillance of patients with ulcerative colitis. Am J Gastroenterol 93 (1998) 872-880
14. Kornbluth A., and Sachar D.B. Ulcerative colitis practice guidelines in adults. American College of Gastroenterology. Practice Parameters Committee. Am J Gastroenterol 92 (1997) 204-211
15. Biasco G., Rossini F.P., Hakim R., Brandi G., Di Battista M., Di Febo G., et al. Cancer surveillance in ulcerative colitis: critical analysis of long-term prospective program. Dig Liver Dis 34 (2002) 339-342
16. Choi P.M., Nugent F.W., Schoetz D.J., Silverman M.L., and Haggit R.C. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 105 (1993) 418-424
17. Koobatian G.J., and Choi P.M. Safety of surveillance colonoscopy in long-standing ulcerative colitis. Am J Gastoroenterol 89 (1994) 1472-1475
18. Matsuhashi N., Nakajima A., Fukushima Y., Yazaki Y., and Oka T. Effects of sulindac on sporadic colorectal adenomatous polyps. Gut 40 (1997) 344-349
19. Vainio H., and Morgan G. Non-steroidal anti-inflammatory drugs and the chemoprevention of gastrointestinal cancers. Scand J Gastroenterol 33 (1998) 785-789
20. Smalley W.R.W., Daugherty J., and Griffin M.R. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 159 (1999) 161-166
21. Courtney E.D.J., Melville D.M., and Leicester R.J. Chemoprevention of colorectal cancer. Aliment Pharmacol Ther 19 (2004) 1-24
22. Allgayer H., and Kruis W. Aminosalicylates: potential antineoplastic actions in colon cancer prevention. Scand J Gastroenterol 37 (2002) 125-131
23. Shanahan F. Colitis-associated cancer - time for new strategies. Aliment Pharmacol Ther 18 Suppl. 2 (2003) 6-9
24. Allgayer H. Mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther 18 Suppl. 2 (2003) 10-14
25. Eaden J. The data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. Aliment Pharmacol Ther 18 Suppl. 2 (2003) 15-21
26. Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 18 Suppl. 2 (2003) 1-5
27. Gwyn K., and Sinicrope F.A. Chemoprevention of colorectal cancer. Am J Gastroenterol 97 (2002) 13-21
28. Baron J.A., Cole B.F., Sandler R.S., Haile R.W., Ahnen D., Bresalier R., et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348 (2003) 891-899
29. Benamouzig R., Deyra J., Martin A., Girard B., Jullian E., Piednoir B., et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 125 (2003) 328-336
30. Chan T.A. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol 3 (2002) 166-174
31. Schwenger P., Alpert D., Skolnik E.Y., and Vilcek J. Activation of p38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IκBα phosphorylation and degradation. Mol Cell Biol 18 (1998) 78-84
32. Kopp E., and Ghosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science 265 (1994) 956-959
33. Anti M., Armuzzi A., and Gasbarrini G. Epithelial cell turnover and apoptosis. Ital J Gastroenterol Hepatol 30 Suppl. 3 (1998) 76-78
34. Renehan A.G., Bach S.P., and Potten C.S. The relevance of apoptosis for cellular homeostasis and tumorigenesis in the intestine. Can J Gastroenterol 5 (2001) 166-176
35. Stack E., and DuBois R.N. Role of cyclooxygenase inhibitors for the prevention of colorectal cancer. Gastroenterol Clin North Am 30 (2001) 1001-1010
36. Kountouras J., Kouklakis G., Zavos C., Chatzopoulos D., Moschos J., Molyvas E., et al. Apoptosis, inflammatory bowel disease and carcinogenesis: overview of international and Greek experiences. Can J Gastroenterol 17 (2003) 249-258
37. Bedi A., Pasricha P.J., Akhtar A.J., Barber J.P., Bedi G.C., Giardiello F.M., et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 55 (1995) 1811-1816
38. Janne P.A., and Mayer R.J. Chemoprevention of colorectal cancer. N Engl J Med 342 (2000) 1960-1968
39. Ota S., Bamba H., Kato A., Kawamoto C., Yoshida Y., and Fujiwara K. COX-2, prostanoids, and colon cancer. Aliment Pharmacol Ther 16 Suppl. 2 (2002) 102-106
40. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., and DuBois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 (1994) 1183-1188
41. Reddy B.S., Tokumo K., Kulkarni N., Aligia C., and Kelloff G. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis 13 (1992) 1019-1023
42. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science 267 (1995) 1456-1462
43. Chan T.A., Morin P.J., Vogelstein B., and Kinzler K.W. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95 (1998) 681-686
44. Ireland A., and Jewell D.P. Mechanisms of action of 5-aminosalicylic acid and its derivatives. Clin Sci 78 (1990) 119-125
45. Bus P.J., Nagtegaal I.D., Verspaget H.W., Lamers C.B.H.W., Geldof H., Van Krieken J.H.J.M., et al. Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era?. Aliment Pharmacol Ther 13 (1999) 1397-1402
46. Reinacher-Schick A., Seidensticker F., Petrasch S., Reiser M., Phlippou S., Theegarten D., et al. Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel. Endoscopy 32 (2000) 245-254
47. Roncucci L., Pedroni M., Vaccina F., Benatti P., Marzona L., and De Pol A. Aberrant crypt foci in colorectal carcinogenesis. Cell and crypt dynamics. Cell Prolif 33 (2000) 1-18
48. Brown W.A., Farmer K.C., Skinner S.A., Malcontenti-Wilson C., Misajon A., and O'Brien P.E. 5-Aminosalicylic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer. Dig Dis Sci 45 (2000) 1578-1584
49. MacGregor D.J., Kim Y.S., Sleisenger M.H., and Johnson L.K. Chemoprevention of colon cancer carcinogenesis by balsalazide: inhibition of azoxymethane-induced aberrant crypt formation in the rat colon and intestinal tumor formation in three B6-Min/+ mouse. Int J Oncol 17 (2000) 173-179
50. Srivastava S., Verma M., and Henson D.E. Biomarkers for early detection of colon cancer. Clin Cancer Res 7 (2001) 1118-1126
51. Weber C.K., Liptay S., Wirth T., Adler G., and Schmid R.M. Suppression of NF-kB activity by sulfasalazine is mediated by direct inhibition of IκB kinases alpha and beta. Gastroenterology 119 (2000) 1209-1218
52. Wahl C., Liptay S., Adler G., and Schmid R.M. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 101 (1998) 1163-1174
53. Bantel H., Berg C., Vieth M., Kruis W., and Shulze-Osthoff K. Mesalazine inhibits activation of transcription factor NF-κB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 95 (2000) 3452-3457
54. Bull A.W. The role of peroxisome proliferator-activated receptor γ in colon cancer and inflammatory bowel disease. Arch Pathol Lab Med 127 (2003) 1121-1123
55. Goke R., Goke A., Goke B., and Chen Y. Regulation of TRAIL-induced apoptosis by transcription factors. Cell Immunol 201 (2000) 77-82
56. Auwerx J. Nuclear receptors. I. PPARγ in the gastrointestinal tract: gain or pain?. Am J Gastrointestinal Liver Physiol 282 (2002) G581-G585
57. Wu G.D. Is there a role for PPARγ in IBD? Yes, no, maybe. Gastroenterology 124 (2003) 1538-1542
58. Peltomaki P. Deficient DNA mismatch repair: a common etiological factor for colon cancer. Hum Mol Genet 10 (2001) 735-740
59. Seril D.N., Liao J., Yang G.Y., and Yang C.S. Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis 24 (2003) 353-362
60. Allgayer H., Hofer P., Schmidt M., Bohne P., Kruis W., and Gugler R. Superoxide, hydroxyl and fatty acid radical scavenging by aminosalicylates. Direct evaluation with electron spin resonance spectroscopy. Biochem Pharmacol 43 (1992) 259-262
61. D'Odorico A., Bortolan S., Cardin R., D'Inca' R., Martines D., Ferronato A., et al. Reduced plasma antioxidant concentrations and increased oxidative DNA damage in inflammatory bowel disease. Scand J Gastroenterol 36 (2001) 1289-1294
62. Kruidenier L., and Verspaget H.W. Oxidative stress as a pathogenic factor in inflammatory bowel disease-radicals or ridiculous?. Aliment Pharmacol Ther 16 (2002) 1997-2015
63. Nishibayashi H., Kanayama S., Shinomura Y., Myagawa J., Ariyoshi T., Toyota M., et al. Decrease of oxidative DNA damage in human colonic mucosa with ulcerative colitis after medical therapy. Gastroenterology 116 (1999) A475
64. Pinczowski D., Ekbom A., Baron J., Yuen J., and Adami H.-O. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 107 (1994) 117-120
65. Franklin J.L., and Rosemberg I.H. Impaired folic acid absorption in inflammatory bowel disease: effects of salicylazosulfapyridine (azulfidine). Gastroenterology 64 (1977) 517-525
66. Moody G.A., Jayanthi V., Probert C.S.J., Mac Kay H., and Mayberry J.F. Long-term therapy with sulfasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicerstershire. Eur J Gastroenterol Hepatol 8 (1996) 1179-1183
67. Eaden J., Abrams K., Ekbom A., Jackson E., and Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 14 (2000) 145-153
68. Kane S.V., Cohen R.D., Aikens J.E., and Hanauer S.B. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 96 (2001) 2929-2933
69. Shale M.J., and Riley S.A. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 18 (2003) 191-198
70. Rubin D.T., Djordjevic A., Huo D., Yadron N., and Hanauer S.B. Use of 5-ASA is associated with decreased risk of dysplasia and colon cancer in ulcerative colitis. Gut 53 Suppl. 3 (2004) 464
71. Croog V., Itzkowitz S., Harpaz N., Kornbluth A., and Ullman T. The effect of mesalamine (5ASA) on progression to colorectal neoplasia in ulcerative colitis (UC). Gastroenterology 126 Suppl. 2 (2004) A20
72. Bjarnason I., Williams P., So A., Zanelli G.D., Levi A.J., Gumpel J.M., et al. Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs. Lancet ii (1984) 1171-1174
73. Bansal P., and Sonnenberg A. Risk factors of colorectal cancer in inflammatory bowel disease. Am J Gastroenterol 91 (1996) 44-48
74. Lashner B.A., Provencher K.S., Seidner D.L., Knesebeck A., and Brzezinski A. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 112 (1997) 29-32
75. Tung B.Y., Emond M.J., Haggitt R.C., Bronner M.P., Kimmey M.B., Kowdley K.V., et al. Ursodiol is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 134 (2001) 89-95
76. Pardi D.S., Loftus Jr. E.V., Kremers W.K., Keach J., and Lindor K.D. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 124 (2003) 889-893
77. Bernstein C.N., Balnchard J.F., Metge C., and Yogendran M. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer?. Am J Gastroenterol 98 (2003) 2784-2788
78. Biasco G., and Zannoni U. Chemoprevention: a new way to face colorectal cancer in ulcerative colitis. Ital J Gastroenterol Hepatol 30 (1998) 426-427
79. Mouzas I.A., Papavassiliou E., and Koutroubakis I. Chemoprevention of colorectal cancer in inflammatory bowel disease? A potential role for folate. Ital J Gastroenterol Hepatol 30 (1998) 421-425
80. Evidence-based Medicine Working Group. Evidence-based medicine: a new approach to teaching the practice of medicine. J Am Med Assoc 268 (1992) 2420-2425
81. Guyatt G.H., et al., for the Evidence-based Medicine Working Group. Users' guides to the medical literature. IX. A method for grading health care recommendations. J Am Med Assoc 274 (1995) 1800-1804
82. Rothenberger D.A. "If you can keep your head..." Clinical decision making in the age of evidence-based medicine. Dis Colon Rectum 47 (2004) 407-412
83. Irvine E.J., and Marshall J.K. Ulcerative, colitis. In: Irvine E.J., and Hunt R.H. (Eds). Evidence-based gastroenterology (2001), Decker BC, Inc, Hamilton, Ont., Canada
84. Mouzas I.A., Papavassiliou E., and Koutroubakis I. Chemoprevention of colorectal cancer in inflammatory bowel disease? A potential role for folate. Ital J Gastroenterol Hepatol 30 (1998) 421-425
85. Lewis J.D., Lichtenstein G.R., Stein R.B., Deren J.J., Judge T.A., Fogt F., et al. An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 96 (2001) 3323-3328
86. Velayos F.S., Walsh J.M., and Terdiman J.P. Effect of 5-aminosalycilate use on colorectal cancer and dysplasia risk in ulcerative colitis: a meta-analysis. Gastroenterology 126 Suppl. 2 (2004) A20
87. Kornbluth A. What happened to drug trials in ulcerative colitis? Problems, PPARs, placebos, and (possible) progress. Am J Gastroenterol 96 (2001) 3232-3234